Oncology

Ultra-processed food consumption linked to an increased risk of developing and dying from ovarian cancer and breast cancer.

Sacituzumab govitecan-hziy (Trodelvy) is a conjugated Trop-2-directed antibody and topoisomerase inhibitor previously approved for patients with triple-negative breast cancer.

Artificial intelligence technology is integrated into the services and products we use every day in our personal and professional lives.

The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma.

In the United States, 91% of states had lower rates of targeted therapy use than expected.

Change is upon us, and opportunities for advancing treatment opportunities for patients continue to look strong.

Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.

New UC Davis study finds relationship between tumor microbiome and immune system in patients with soft tissue sarcoma.

Patients who received first-line ICI showed a significant improvement in progression-free survival (PFS) and overall survival (OS) compared to chemotherapy treatment.

Pembrolizumab approved as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer.

Findings suggest cancer may have overtaken cardiovascular disease as a leading cause of death in individuals with type 2 diabetes.

Relatively higher suicide risks were observed for cancer types with a poor prognosis and high symptom burden in the first 2 years after diagnosis.

Most individuals who used cannabis to manage their chronic pain reported using it in place of other pain medications, including opioids.

Chronochemotherapy aims to time drug delivery when the body is the least vulnerable to harmful effects, while the cancer cells are the most vulnerable.

At leukapheresis, a low frequency of differentiated CD3+CD27-CD28--T cells can indicate favorable response to CAR T-cell therapy.

Zolbetuximab treatment reduced risk of death by 25% compared to placebo.

Specific data and results for pembrolizumab in patients with advanced or unresectable biliary tract cancer will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

New findings reveal the previously misunderstood mechanism by which PCSK9 degrades the low-density lipoprotein receptor.

In patients with HER2-expressing metastatic gastroesophageal adenocarcinoma administered zanidatamab, the median duration of response was 20.4 months, with a median progression-free survival of 12.5 months.

Overall survival data were immature at the time of interim analysis and follow-up will continue to the next analysis.

During the COVID-19 pandemic, patients were able to utilize telehealth services to receive care more conveniently, which may reduce the cost of care.

Patients who received the interventions reported improved anxiety and pain levels.

OR-449 is being developed for both adult and pediatric patients with adrenocortical carcinoma, as well as other cancers known to express a high level of steroidogenic factor-1.

CAR T cell gel eliminated the residual tumor cells in almost all mouse models, allowing the mice to survive when they otherwise would have succumbed to tumor recurrence.

Sarah McDonald, cancer survivor and author of The Cancer Channel, discusses her experience battling 2 different unrelated cancers and the value oncology pharmacists could have provided with a greater presence on her care team.

Many patients have baseline risk factors present at diagnosis because of older age and disease-related elements.

18F-FDG PET/CT detects approximately 73% of tumor lesions, while 68Ga-FAPI finds approximately 94%.

Bruton’s tyrosine kinase inhibitor zanubrutinib (Brukinsa; BeiGene USA, Inc) approved for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

This is the first indication for tucatinib that extends beyond the treatment of advanced unresectable or metastatic HER2-positive breast cancer.

Older patients received cancer treatment less frequently during the pandemic, as did patients covered by Medicaid.